CLINICAL_TRIALS
trial_result
· 2025-09-12
Clinical Trial Update: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma [Phase 1]
Summary
Sanofi completed a first-in-human Phase 1 trial of SAR442085 as a single-agent therapy for relapsed or refractory multiple myeloma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Plasma Cell Myeloma | Phase 1 | Status: COMPLETED